Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WS 1070
- Development stage
- Phase 4
- Lead developer
- Schwabe
- Administration
- Oral
01
Overview
WS 1070 is a proprietary, standardized herbal extract of *Eleutherococcus senticosus* (Siberian ginseng) developed by Dr. Willmar Schwabe GmbH & Co. KG. Classified as an adaptogen, it is designed to enhance the body's non-specific resistance to various physical and mental stressors. The extract is primarily indicated for the treatment of symptoms associated with asthenia, such as fatigue, weakness, and decreased concentration capacity. Its mechanism of action involves the modulation of the hypothalamic-pituitary-adrenal (HPA) axis and the neuroendocrine system to support resilience and recovery from stress. WS 1070 has been evaluated in Phase IV clinical trials, including studies investigating its synergistic effects when combined with structured stress management programs.
- Other names
- Siberian ginseng extractEleutherococcus senticosus extract
Beyond the preview
Go deeper on WS 1070.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WS 1070.